Kowalski et al., 2011 - Google Patents
Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen‐specific IgE antibodiesKowalski et al., 2011
- Document ID
- 6918519932979049307
- Author
- Kowalski M
- Cieślak M
- Perez‐Novo C
- Makowska J
- Bachert C
- Publication year
- Publication venue
- Allergy
External Links
Snippet
To cite this article: Kowalski ML, Cieślak M, Pérez‐Novo CA, Makowska JS, Bachert C. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen‐specific IgE antibodies. Allergy 2011; 66: 32–38. Abstract …
- 208000006673 Asthma 0 title abstract description 155
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Health care, e.g. hospitals; Social work
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kowalski et al. | Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen‐specific IgE antibodies | |
Song et al. | Staphylococcal enterotoxin IgE sensitization in late‐onset severe eosinophilic asthma in the elderly | |
Ferastraoaru et al. | Eosinophilia in asthma patients is protective against severe COVID-19 illness | |
Siroux et al. | Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study | |
Workman et al. | Biomarkers in chronic rhinosinusitis with nasal polyps | |
Pillai et al. | Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma | |
Kupczyk et al. | US and European severe asthma cohorts: what can they teach us about severe asthma? | |
McCracken et al. | Diagnosis and management of asthma in adults: a review | |
Bach et al. | Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence | |
Lee et al. | Lifetime exposure to cigarette smoking and the development of adult‐onset atopic dermatitis | |
Wilkes et al. | Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis | |
Hohlfeld et al. | Diagnostic value of outcome measures following allergen exposure in an environmental challenge chamber compared with natural conditions | |
Chung | Diagnosis and management of severe asthma | |
Lommatzsch et al. | IgE is associated with exacerbations and lung function decline in COPD | |
Lee et al. | Characteristics of Specialist‐Diagnosed Asthma‐COPD Overlap in Severe Asthma: Observations from the Korean Severe Asthma Registry (KoSAR) | |
Wood et al. | Mannitol challenge for assessment of airway responsiveness, airway inflammation and inflammatory phenotype in asthma | |
Konradsen et al. | High basophil allergen sensitivity (CD‐sens) is associated with severe allergic asthma in children | |
Colas et al. | Needs for systems approaches to better treat individuals with severe asthma: predicting phenotypes and responses to treatments | |
Manoharan et al. | The potential role of direct and indirect bronchial challenge testing to identify overtreatment of community managed asthma | |
Andrade et al. | Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study | |
Wade et al. | Evaluation and treatment of critical asthma syndrome in children | |
Holgate et al. | The future of asthma care: Personalized asthma treatment | |
Mummadi et al. | Clinically significant variability of serum IgE concentrations in patients with severe asthma | |
Marion et al. | Asthma in cystic fibrosis: definitions and implications of this overlap syndrome | |
Flora et al. | Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients |